Abbad-Jaime De Aragón, CarlotaBerna-Rico, EmilioJaén, PedroBlauvelt, AndrewGonzález-Cantero, Álvaro2025-12-222025-12-222025Abbad-Jaime De Aragón, C, Berna-Rico, E, Jaén, P, Blauvelt, A & González-Cantero, Á 2025, 'Bimekizumab as-needed dosing in patients with psoriasis : a case series', Journal of Dermatological Treatment, vol. 36, no. 1, 2492197. https://doi.org/10.1080/09546634.2025.24921970954-6634https://hdl.handle.net/10641/6856Publisher Copyright: © 2025 The Author(s). Published with license by Taylor & Francis Group, LLC.Introduction: Despite significant advances in psoriasis treatment, off-label dosing studies of psoriasis biologic therapies are limited. Materials and methods: In this retrospective case series, medical records from 28 patients with moderate-to-severe psoriasis treated with bimekizumab during 64-week period from May 2023 to October 2024 at the Psoriasis Unit of the Grupo Jaen (Madrid, Spain), were evaluated. Patients were managed with an off-label, as-needed, dosing strategy, with all patients initially receiving two 320 mg doses of bimekizumab at Weeks 0 and 4; subsequent doses were administered only if a given patient dropped below a PASI90 response. Primary outcome was the percentage of patients that achieved and maintained optimal skin control over time, defined as achieving a PASI90 response. Results: Twenty-seven out of the 28 patients achieved a PASI90 response after the first two bimekizumab doses, and all maintained PASI90 responses with as-needed dosing over time. One patient achieved PASI90 after a single dose of bimekizumab, and voluntarily decided not to receive a second dose. No adverse events were observed. Conclusions: Larger prospective studies comparing efficacy and safety of this off-label, as needed, bimekizumab dosing regimen with standard on-label dosing are necessary to corroborate these findings.1451728enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Psoriasisbimekizumabdose reductionon-demandDermatologyJournal ArticleYesyesjournal articleopen access10.1080/09546634.2025.2492197https://www.scopus.com/pages/publications/105003399675https://www.scopus.com/pages/publications/105003399675#tab=citedBy